Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O’Nions, D. Peters, Christine M. McMahon, Ronan Swords, Rachel C. Cook, Jennifer N. Saultz, Jeffrey Tyner, Richard Dillon, Joshua F. Zeidner, Daniel A. Pollyea
Abstract
ABSTRACT: The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.
Topics & Concepts
VenetoclaxMyeloid leukemiaMedicineOncologyRisk stratificationInternal medicineHypomethylating agentLeukemiaIntensive care medicineGeneBiologyGeneticsDNA methylationChronic lymphocytic leukemiaGene expressionAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments